← Leaderboards
Karen Weber Makar
Fred Hutchinson Cancer Research Center
$255,095
Attributed
$255,095
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $88K · FY2009–13$100K$75K$50K$25K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$255,095 · 2
By mechanism
R03$255,095 · 2
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Cornelia M Ulrich$28,998,049
- Danny D Shen$3,012,784
- Polly A Newcomb$32,889,977
- Ulrike Peters$61,091,539
- Janet L Stanford$12,426,000
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsPreventRecurrenceColon CarcinomaHigh RiskMalignant NeoplasmsColorectal CancerBaseAspirinAftercareCancer CareCancer DetectionCancer DiagnosisCancer EtiologyBlood CirculationBloodArachidonate 5-LipoxygenaseCause Of DeathCell PhysiologyCessation Of LifeChemopreventionChemopreventive AgentClinical PracticeCancer Recurrence
Grant awards (3)
Circulating microRNAs as a biomarker of colorectal cancer recurrence$82,720
R03 · FY2013 · CA · contact PI
Circulating microRNAs as a biomarker of colorectal cancer recurrence$88,000
R03 · FY2012 · CA · contact PI
Aspirin pharmacogenetics in the Aspirin/Folate Polyp Prevention Trial$84,375
R03 · FY2009 · CA · contact PI